4ogt: Difference between revisions
m Protected "4ogt" [edit=sysop:move=sysop] |
No edit summary |
||
Line 1: | Line 1: | ||
{{STRUCTURE_4ogt| PDB=4ogt | SCENE= }} | |||
===Co-Crystal Structure of MDM2 with Inhbitor Compound 46=== | |||
{{ABSTRACT_PUBMED_24601644}} | |||
==Disease== | |||
[[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | |||
==Function== | |||
[[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as an ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and promotes it to proteasomal degradation.<ref>PMID:12821780</ref> <ref>PMID:15053880</ref> <ref>PMID:15195100</ref> <ref>PMID:16337594</ref> <ref>PMID:15632057</ref> <ref>PMID:17290220</ref> <ref>PMID:19098711</ref> <ref>PMID:19219073</ref> <ref>PMID:19965871</ref> <ref>PMID:20858735</ref> <ref>PMID:20173098</ref> | |||
==About this Structure== | |||
[[4ogt]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OGT OCA]. | |||
==Reference== | |||
<ref group="xtra">PMID:024601644</ref><references group="xtra"/><references/> | |||
[[Category: Huang, X.]] | |||
[[Category: Long, A M.]] | |||
[[Category: Shaffer, P L.]] | |||
[[Category: Yakowec, P.]] | |||
[[Category: Ligase-ligase inhibitor complex]] | |||
[[Category: P53]] | |||
[[Category: Protein-protein interaction]] |